These findings collectively reinforce the hypothesis that RSPRY1 deficiency disrupts the balance of TGF-β signaling, driving the molecular and cellular dysfunctions underlying SEMD; however, some limitations must be acknowledged when interpreting these findings. This evidence concerns the gene TGFB1 and spondyloepimetaphyseal dysplasia.